Charlie Puth Cancels Six Australia, New Zealand Shows

Telix agrees to acquire ITM for $1.65 billion upfront

Telix Pharmaceuticals agreed to acquire ITM Isotope Technologies Munich for US$1.65 billion in a largely share-based deal with debt assumption and up to US$700 million in milestone payments, creating a vertically integrated radiopharmaceutical group expected to post pro forma 2026 revenue above US$1.3 billion. The transaction, which positions Telix to accelerate into the commercial radionuclide therapy market and leverages ITM’s leading production capabilities and ITM-11’s Phase 3 pipeline, remains subject to shareholder and regulatory approvals with closing targeted by the end of FY2026.